Mylotarg (Gemtuzumab ozogamicin) for injection 5 mg/Vial ^

Mylotarg (gemtuzumab ozogamicin) for injection 5 mg/Vial is a prescription medication used to treat acute myeloid leukemia (AML), a type of cancer that affects the blood cells. It contains the active ingredient gemtuzumab ozogamicin, which is a type of medicine called a monoclonal antibody-drug conjugate.

AML is a cancer that starts in the bone marrow, where blood cells are produced. Gemtuzumab ozogamicin works by attaching to a protein called CD33, which is found on the surface of AML cells. This helps to trigger the immune system to attack and destroy the cancer cells. Mylotarg is given as an injection into a vein, typically once a week for 3 weeks. The dose and duration of treatment will depend on several factors, including the type and severity of the cancer and how well the patient responds to the medication.

Common side effects of Mylotarg may include nausea, vomiting, fever, and low blood counts. These side effects are usually mild and go away on their own, but if they persist or become severe, it is important to contact your doctor. Mylotarg may also interact with certain other medications, so it is important to inform your doctor of all the drugs you are taking.

Studies have shown that Mylotarg can be an effective treatment for AML. In a clinical trial published in the New England Journal of Medicine, Mylotarg was shown to improve overall survival in patients with newly diagnosed AML compared to chemotherapy alone. Another study published in the journal Blood found that Mylotarg was effective at reducing the risk of disease progression and improving overall survival in patients with relapsed or refractory AML.

In summary, Mylotarg (gemtuzumab ozogamicin) for injection 5 mg/Vial is a prescription medication used to treat acute myeloid leukemia (AML). It contains the active ingredient gemtuzumab ozogamicin, which attaches to a protein on the surface of AML cells, triggering the immune system to attack and destroy the cancer cells. Several studies have shown that Mylotarg can be an effective treatment for AML, improving overall survival and reducing the risk of disease progression. It is given as an injection into a vein, and the dose and duration of treatment will be determined by your doctor.

Additional Information:
One of the following licensed pharmacy from the nearest location will deliver Mylotarg (Gemtuzumab ozogamicin) for injection 5 mg/Vial ^. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts your request based on valid prescription and availability.